Full-Time

Clinical Research Senior Medical Scientist

Endocrinology

Posted on 4/9/2025

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

$168.7k - $218.9k/yr

+ Bonus + Stock-based long-term incentives

Senior

Remote in USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Biology & Biotech
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Amgen referral from your network.

đź’ˇ

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Doctorate degree and 2 years of experience in clinical trials implementation in obesity, diabetes, or metabolic diseases
  • Master’s degree and 4 years of experience in clinical trials implementation in obesity, diabetes, or metabolic diseases
  • Bachelor’s degree and 6 years of experience in clinical trials implementation in obesity, diabetes, or metabolic diseases
  • Associate’s degree and 10 years of experience in clinical trials implementation in obesity, diabetes, or metabolic diseases
Responsibilities
  • Support cross-functional and global collaborations to integrate broad medical, scientific, and commercial input into the clinical development program.
  • Participate and provide clinical input into safety and regulatory interactions.
  • Provide clinical/scientific input during the development and execution of clinical trials.
  • Review data from clinical trials related to medical monitoring, as well as support and address questions from sites and from investigators.
  • As needed, provide clinical/scientific input into, author sections of, and QC study-related documents (e.g. study concept documents and protocols).
  • Interpret clinical trial data and participate in safety assessments.
  • Review and provide clinical scientific input to safety narratives.
  • Initiate database analyses to support commercial/clinical objectives.
  • Contribute to the preparation of clinical study reports and regulatory submissions.
  • Support interactions with regulatory agencies if needed.
  • Develop key opinion leaders and make scientific presentations at advisory boards, key scientific meetings and external committee meetings as delegated by the GDL or delegee and help identify new clinical research opportunities.
Desired Qualifications
  • Accredited residency in Endocrinology, board certified or equivalent 2+ years of clinical research experience and/or basic science research combined with clinical teaching and patient care activities
  • MD preferred.
  • Prior research in obesity, diabetes, or metabolic diseases preferred.
  • An understanding of the scientific method and clinical applications based medical, scientific and practical rationale
  • Familiarity with concepts of clinical research and clinical trial design and execution including biostatistics
  • Familiarity with regulatory agency organization, guidelines, and practices
  • Ability to effectively present ideas and document complex medical/clinical concepts in both written and oral communication
  • History of solving problems, especially in implementation of clinical trials while exhibiting superior judgment and balanced, realistic understanding of issues.

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are medicines made from living organisms. These therapies target conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen stands out from competitors by reinvesting a large portion of its earnings into research and development, ensuring a strong pipeline of new treatments. The goal of Amgen is to improve patient care by providing effective therapeutic solutions for serious health issues.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.

INACTIVE